FIGURE 4.
Summary of treatment and outcomes in patients with higher‐risk MDS after AZA failure according to the Revised International Prognostic Scoring System Karyotype. AZA, Azacitidine; MDS, myelodysplastic syndromes; OS, overall survival
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.